II. MATERIALS AND METHODS
4. Immunological and physico-chemical analysis of scFv
4.2. Physico-chemical analysis
4.2.1 Circular Dichroism Detector
Secondary structure of scFv and MBP fusion proteins in PBST buffer was analyzed by circular dichroism detector (Chirascan plus, Applied Photophysics, UK). Detector was High performance UV-Vis-IR avalanche photo-diode fluorescence monochro detector. Analyzing temperature was 25°C. Cell path length was 0.5 mm. Wavelength of CD was 190 ~ 250 nm to analyze secondary structure of proteins. PBST buffer was analyzed to determined baseline. Factor Xa protease treatment was conducted to obtain scFv without MBP to analyze secondary structure. Though, pure scFv itself was extremely unstable and remained as insoluble aggregate (Fig. 30). Thus, MBP and scFv-MBP fusion protein were analyzed. Absorbance difference of MBP and MBO-scFv was analyzed.
29
5. Application of expression system to other types of scFv 5.1 Fumonisin B
1scFv
5.1.1 Expression of fumonisin B
1scFv and MBP fusion protein in E. coli C41(DE3) strain
E. coli BL21(DE3) and C41(DE3) carrying fumonisin B1 scFv and MBP fusion protein plamids were inoculated in LB medium baffled flask and grown at 37°C, 250 rpm. Expression of proteins was induced by the addition of isopropyl-2-D-thio-galactopyranoside (IPTG) to final concentration of 0.2 mM. Expression was analyzed by SDS-PAGE.
5.2 Deoxynivalenol scFv
5.2.1 Expression of deoxynivalenol scFv and MBP fusion protein in E. coli C41(DE3) strain
E. coli BL21(DE3) and C41(DE3) carrying deoxynivalenol scFv and MBP fusion protein plamids were inoculated in LB medium baffled flask and grown at 37°C, 250 rpm. Expression of proteins was induced by the addition of isopropyl-2-D-thio-galactopyranoside (IPTG) to final concentration of 0.2 mM. Expression was analyzed by SDS-PAGE.
30
Table 4. Sequence of the primers used in this research
Primer name Primer sequences
(5’-3’)
MalE-BspHI-F AAG CTT TC ATG AAA ATA AAA ACA GGT GCA CGC MalE-NdeI-R AAT CGC CAT ATG CCT TCC CTC GAT CCC GAG GTT pelBscFv AFB-BspHI-F AAG CTT TC ATG AAA TAC CTG CTG CCG ACC
pelBscFv AFB-NdeI AAT CGC CAT ATG CCT TCC CTC GAT ACC TAG GAC GAG TTT GGT TCC TC
scFv AFB H6-BamH1-R AAT CGC GGA TCC TTA GTG GTG GTG GTG GTG GTG C His6 scFv AFB-Nde1-F AAT CGC CAT ATG CAC CAC CAC CAC CAC CAC ATG GAG GTG AAG
CTG CAG
His6 scFv AFB Xa-xho1-R AAT CGC CTC GAG CCT TCC CTC GAT ACC TAG GAC GAG TTT GGT TCC TC
malE-xhoI-F2 AAT CGC CTC GAG AAA ATC GAA GAA GGT AAA CTG GTA ATC malE-BamHI-R2 AAT CGC GGA TCC TTA CCC GAG GTT GTT GTT ATT GTT ATT G scFv AFB1 H6-Nde1-IF-F TCGAGGGAAGGCATATGGAGGTGAAGCTGCAGGAGTCTG scFv AFB1 H6-BamH1-IF-R GTTAGCAGCCGGATCCTTAGTGGTGGTGGTGGTGGTGC
31
scFv op. H6-Nde1-IF-F TC GAG GGA AGG CAT ATG GAA GTG AAA CTG CAG GAA AGC G scFv op. H6-BamH1-IF-R G TTA GCA GCC GGA TCC TCA GTG GTG GTG GTG GTG GTG C
pelB scFv op. - Nde1 – F AAT CGC CAT ATG AAA TAC CTG CTG CCG ACC GC pelB scFv op. Xa - xho1 – R AAT CGC CTC GAG CCT TCC CTC GAT GCC CAG CAC CAG TTT GGT G
malE H6-BamHI-R2 AAT CGC GGA TCC TTA GTG GTG GTG GTG GTG GTG CCC GAG GTT GTT GTT ATT GTT ATT G
malE Xa – BspH1-F AAG CTT TC ATG AAA ATC GAA GAA GGT AAA CTG ATC H6 scFv op Xa – Nde1 – F AATCGCCATATGCACCACCACCACCACCAC ATG GAA GTG AAA CTG
CAG GAA AGC
H6 scFv op Xa – Xho1 – R AAT CGC CTC GAG CCT TCC CTC GAT GCC CAG CAC CAG TTT GGT G pelB scFv op. Xa – BspH1 – F AAG CTT TC ATG AAA TAC CTG CTG CCG ACC GC
pelB scFv op. Xa – Nde1 – R AAT CGC CAT ATG CCT TCC CTC GAT GCC CAG CAC CAG TTT GGT G malE H6-Nde1-F2 AAT CGC CAT ATG AAA ATC GAA GAA GGT AAA CTG GTA ATC malE H6-XhoI-R2 AAT CGC CAT ATG AAA ATC GAA GAA GGT AAA CTG GTA ATC FB1 scFv - Nde1 – F AAT CGC CAT ATG GAT GTA GTC ATG ACC CAG TCT CC FB1 scFv - BamH1 – R AAT CGC GGA TCC TCA GTG GTG GTG GTG GTG GTG
DON scFv - Nde1 – F AAT CGC CAT ATG CAG GTG AAG CTG CAG CAG TCT G DON scFv - BamH1 – R AAT CGC GGA TCC TCA GTG GTG GTG GTG GTG GTG
32
MKIKTGARILALSALTTMMFSASALAKIEEGKLVIWINGDKGYNGLA EVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFG GYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSL IYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIA ADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNA DTDYSIAEAAFNKGETAMTINGPWAWSNIDTSKVNYGVTVLPTFKG QPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPL GAVALKSYEEELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRT AVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGIEGRHMEV KLQESGGGLVKPGGSLKLSCAASGFTFSTYAMSWVRQTPEKRLEWV ATISSGGTYTYSPDSVKGRFTISRDNAKNTLYLQMSSLRSEDTAMYY CASHGLLWSFAYWGQGTTVTVSSGGGGSGGGGSGGGGSQAVVTQE SALTTSPGETVTLTCRSSTGAVTTSNSANWVQEKPDHLFTGLIGGTN NRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNHLVFG GGTKLVLGLEHHHHHH
Fig. 6. Amino acid sequence of AFB1 scFv and MBP fusion protein
33
MDVVMTQSPLTLSVTIGQPASISCKSSQSLLDSDGKTYLNWLLQRPG QSPKRLIYLVSKLDSGFPDRFTGSGSGTDFTLKISRVEAEDLGVYYCW QGIHFPRTFGGGTKLEMGGGGSGGGGSGGGGSEVQLQQSGAELVKP GASVKLSCKTSGYTFTSYWIQWVKQRPGQGLGWIGEIFPGTGTTYY NEKFKGKATLTIDTSSSTVYMQLSSLTSEDSAVYFCASRRFAYWGQG TTVTVSSLEHHHHHH
Fig. 7. Amino acid sequence of fumonisin B1 scFv with 6 histidine tag
MQVKLQQSGTEVVKPGASVKLSCKASGYIFTSYDIDWVRQTPEQGL EWIGWIFPGEGSTEYNEKFKGRATLSVDKSSSTAYMELTRLTSEDSA VYFCARGDYYRRYFDLWGQGTTVTVSSGGGGSGGGGSGGGGSQAV VTQESALTTSPGGTVILTCRSSTGAVTTSNYANWVQEKPDHLFTGLI GGTSNRAPGVPVRFSGSLIGDKAALTITGAQTEDDAMYFCALWYST HFVFGGGTKVTVLGLEHHHHHH
Fig. 8. Amino acid sequence of deoxynivalenol scFv with 6 histidine tag
34
Fig. 9. Codon usage table of non-codon optimized scFv gene in E. coli
35
Fig. 10. Codon usage table of codon optimized scFv gene in E. coli
36
Fig. 11. Purification process
Cell lysis by sonication
Collection of soluble fraction
Affinity chromatography (Histag purification)
Desalting
(Buffer change to PBST buffer
for ELISA)
37
Fig. 12. Diagram of indirect ELISA
38
III. RESULTS AND DISCUSSIONS
1. Plasmids and strains
1.1 Construction of expression plasmids and strains
To obtain soluble and functional scFv in vivo, maltose binding protein which is expressed in high solubility in E. coli was fused with AFB1 scFv.
Direction of MBP fusion to scFv such as N or C-terminal influences expression of proteins. Both direction fusion protein expression plasmids were constructed with scFv and codon optimized scFv gene. Factor Xa protease site was inserted between scFv and MBP gene. For purification, 6 hisitidine tag was combined into the expression plasmids. pET19b s.s. malE Xa scFv H6 and pET19b H6 scFv Xa malE plasmids were constructed for non-codon optimized gene. pET19b s.s malE Xa scFv op H6, pET19b pelB scFv op Xa malE H6, pET19 malE Xa scFv op H6, and pET19 H6 scFv op Xa malE were constructed for codon optimized scFv gene. All plasmids usded and constructec in this research are summarized from fig. 13 to 16 and Table 5.
39
2. Expression of proteins
2.1 scFv and MBP fusion protein expression
In order to express soluble and active scFv and elevate the expression level of scFv, maltose binding protein was fused. pET19 s.s malE Xa scFv H6 and pET19 H6 scFv Xa malE were expressed in E. coli BL21(DE3).
Control strains are E. coli BL21(DE3) carrying scFv gene without MBP fusion protein.
Maltose binding protein fusion slightly elevated the expression level in E.
coli BL21(DE3) strains (Fig. 17 and Fig. 18). However, majority of expressed scFv and MBP fusion protein was insoluble. Experimental results gave no positive effect on sloluble expression.
2.2 Codon optimized and non-codon optimized scFv gene expression in diverse E. coli host strains.
Codon optimized scFv gene to optimized translation in E. coli was fused with maltose binding protein in N and C-terminal. Periplasmic targeting signal sequence of pelB or maltose binding protein itself was inserted in express vectors.
Some of MBP fusion optimized scFv expressed in BL21(DE3), though expression pattern was insoluble (Fig. 19 to 20). N-terminal MBP fusion
40
scFv with signal sequence in C41(DE3) host expressed in soluble form. (Fig.
22) Fusion protein without signal sequence was expressed in Origami (DE3) strains (Fig. 23). scFv and MBP protein expression in Origami (DE3) strains was no positive effect (Fig 24).
To verify the direction of fusion protein and compare with these result of experiments with non-codon optimized scFv gene, non-codon optimized gene was fused with maltose binding protein in N and C-terminal of scFv.
Like the preceding, N-terminal MBP fusion scFv with signal sequence in C41(DE3) was solely expressed soluble form of proteins (Fig. 21). These results suggested that expression system of scFv and MBP fusion in E. coli C41(DE3) strains enhanced soluble expression level of scFv proteins.
2.3 Fed-batch fermentation
Fed-batch fermentations were conducted with the recombinant strains which produced the largest amount of solube scFv and MBP fusion proteins – C41(DE3) carrying pET19 s.s malE Xa scFv H6. After initial glucose concentration of 20 g/L was completely exhausted, the operation mode was switched to the pH-stat fed-batch by using feeding solution. When O.D.at 600 nm reached 80 ~ 100, IPTG (0.2 mM) were added.
The pH-stat fed-batch fermentation of BL21 (DE3) /pET19b s.s malE Xa
41
scFv H6 resulted in 49.275 g/L dry cell weight, 810 mg/L scFv and MBP fusion protein concentration (Fig. 25). Total glucose consuption was 310 g.
Soluble fraction of scFv and MBP fusion protein produced by fed-batch fermentation had purification of affinity chromatography. Fed-batch profile is shown (Fig. 25).
3. Purification and quantitative analysis of scFv
For the efficient purification of the scFv and MBP fusion proteins, 6 His residues were fused. The HisTrap FF column (GE healthcare, Sweden) specific for His 6 residues was used. FPLC was operated to purify histagged scFv and MBP proteins. SDS-PAGE analysis indicated that the target antibody was purified and detected at the size of molecular weight of 27 kDa.
(Fig. 26) These results indicate that construction of in vivo scFv and MBP fusion protein production system.
To quantify the scFv and MBP fusion proteins, standard curve using BSA solution was prepared. Using standard curve, scFv and MBP fusion protein was quantified to be used for immunological and physic-chemical analysis.
42
4. Immunological and physic-chemical analysis 4.1 Indirect ELISA
To analyze binding activity of AFB1 scFv and MBP fusion protein to aflatoixn B1, indirect ELISA was carried out. The detection limit of aflatoxin B1 was 50 ppb (ng/ml). Antigen-binding activity was confirmed by increasing signal of scFv and MBP fusion proteins according to increasing concentration of antigen (Fig. 27 to Fig. 29).
4.2 Circular dichroism
To analyze secondary structure of scFv, circular cichroism was carried out.
Alpha helix rich protein has round lowest point at 208 and 222 nm. Beta sheet rich protein has point at 218 nm. Secondary structure of scFv is beta sheet rich protein. MBP describe as most secondary structure is involved in alpha-helical structure. Signal of scFv and MBP fusion protein minus signal of MBP protein is scFv signal. These subtraction result present that scFv has beta sheet rich secondary structure and folded properly (Fig. 31).
43
5. Application of expression system to other types of scFv 5.1 Fumonisin B
1scFv
Above-described, expression system of scFv and MBP fusion in E. coli C41(DE3) strains enhanced soluble expression level of scFv proteins. There are two types of scFv according to the light chain such as lambda and kappa.
For broad applications of this expression s system, other types of scFv were examined. Aflatoxin B1 scFv is lambda type. Fumonisin B1 scFv from Jun-Bock Park is kappa type scFv. After analyzing the expression of scFv and MBP fusion protein using this expression system by SDS-PAGE, there was positive effect on soluble expression (Fig. 32).
5.2 Deoxynivalenol scFv
Deoxynivalenol scFv from Gyu-Ho Choi is lambda type like aflatoxin B1
scFv. . After analyzing the expression of scFv and MBP fusion protein using this expression system by SDS-PAGE, there was positive effect on soluble expression. Gathering up these results from aflatoxin B1 scFv, fumonisin B1
scFv, and deoxynivalenol scFv, it propose that expression system of scFv and MBP fusion protein expression in E. coli C41(DE3) has certain effect on producing soluble scFv (Fig. 33).
44
Fig. 13. Genetic map of non-codon optimized scFv gene for aflatoxin B1
pET19b.
45
Fig. 14. Genetic map of codon optimized scFv gene with signal sequence for aflatoxin B1
46
Fig. 15. Genetic map of codon optimized scFv gene without signal sequence for aflatoxin B1
47
Fig. 16. Genetic map of fumonisin B1 and deoxynivalenol scFv gene with signal sequence for aflatoxin B1
pET19b.
48
Table 5. Constructed strains used in this research
Strain Plasmids
E. coli BL21(DE3)
pET19b s.s malE Xa scFv H6 E. coli C41(DE3)
E. coli BL21(DE3)
pET19b H6 scFv Xa malE E. coli C41(DE3)
pET19b pelB scFv op Xa malE H6 E. coli C41(DE3)
49
Fig. 17. Expression of non-MBP fusion scFv in BL21(DE3) at 37°C and 0.2 mM IPTG.
L T S I T S I
30 kDa 40 kDa 50 kDa
25 kDa
BL21(DE3)/pET26 pelB scFv H6
AFB1 scFv : 26.5 kDa MBP: 42 kDa
scFv-MBP fusion protein: 68.5 kDa
L : Protein Ladder
T : Total (Before Induction) T: Total (After Induction) S : Soluble (After Induction) I : Insoluble (After Induction)
50
Fig. 18. Expression of MBP fusion scFv in BL21(DE3) at 37°C and 0.2 mM IPTG.
AFB1 scFv : 26.5 kDa MBP: 42 kDa
scFv-MBP fusion protein: 68.5 kDa
L : Protein Ladder
T : Total (Before Induction) T: Total (After Induction) S : Soluble (After Induction) I : Insoluble (After Induction)
BL21(DE3) pET19b s.s malE Xa scFv H6
40 kDa
BL21(DE3)/pET19b H6 scFv Xa malE
51
Fig. 19. Expression of MBP fusion codon optimized scFv with signal sequence in BL21(DE3) at 37°C and 0.2 mM IPTG.
BL21(DE3)/ pET19b s.s malE Xa scFv op. H6
30 kDa 40 kDa 50 kDa 60 kDa 70 kDa
BL21(DE3)/pET19b pelB scFv op. Xa malE H6
L T L T S I
AFB1 scFv : 26.5 kDa MBP: 42 kDa
scFv-MBP fusion protein: 68.5 kDa
L : Protein Ladder
T : Total (Before Induction) T: Total (After Induction) S : Soluble (After Induction) I : Insoluble (After Induction)
52
Fig. 20. Expression of MBP fusion codon optimized scFv without signal sequence in BL21(DE3) at 37°C and 0.2 mM IPTG.
BL21(DE3)/pET19b malE Xa scFv op. H6
30 kDa 40 kDa 50 kDa 60 kDa 70 kDa
BL21(DE3)/pET19b H6 scFv op. Xa malE
T T S I L
AFB1 scFv : 26.5 kDa MBP: 42 kDa
scFv-MBP fusion protein: 68.5 kDa
L : Protein Ladder
T : Total (Before Induction) T: Total (After Induction) S : Soluble (After Induction) I : Insoluble (After Induction)
53
Fig. 21. Expression of MBP fusion scFv in C41(DE3) at 37°C and 0.2 mM IPTG.
C41(DE3)/pET19 H6 scFv Xa malE
30 kDa
C41(DE3)/pET19 s.s malE Xa scFv H6
30 kDa
scFv-MBP fusion protein: 68.5 kDa
L : Protein Ladder
T : Total (Before Induction) T: Total (After Induction) S : Soluble (After Induction) I : Insoluble (After Induction)
54
Fig. 22. Expression of MBP fusion codon optimized scFv with signal sequence in C41(DE3) at 37°C and 0.2 mM IPTG.
C41(DE3)/pET19b s.s malE Xa scFv op. H6
L T L
T SI
C41(DE3)/pET19b pelB scFv op. Xa malE H6
L T
TL
SI
AFB1 scFv : 26.5 kDa MBP: 42 kDa
scFv-MBP fusion protein: 68.5 kDa
L : Protein Ladder
T : Total (Before Induction) T: Total (After Induction) S : Soluble (After Induction) I : Insoluble (After Induction)
55
Fig. 23. Expression of MBP fusion codon optimized scFv without signal sequence in C41(DE3) at 37°C and 0.2 mM IPTG.
C41(DE3)/pET19b malE Xa scFv H6
30 kDa
C41(DE3)/pET19b H6 scFv op Xa malE
T
T S IL
AFB1 scFv : 26.5 kDa MBP: 42 kDa
scFv-MBP fusion protein: 68.5 kDa
L : Protein Ladder
T : Total (Before Induction) T: Total (After Induction) S : Soluble (After Induction) I : Insoluble (After Induction)
56
Fig. 24. Expression of MBP fusion codon optimized scFv without signal sequence in Origami (DE3) at 37°C and 0.2 mM IPTG
Origami (DE3)/ pET19b malE Xa scFv op H6
30 kDa
Origami (DE3)/pET19 H6 scFv op Xa malE
30 kDa
scFv-MBP fusion protein: 68.5 kDa
57
Fig 25. Profile of fed-batch fermentation Time (h)
58
Fig 26. Purification of scFv and MBP fuison protein
30 kDa
scFv-MBP fusion protein: 68.5 kDa
59
Fig 27. Antigen (aflatoxin B1) binding activity of non-codon optimized scFv and MBP fuison protein by indirect ELISA
MBP-scFv ELISA
Con. of aflatoxin (ppb)
1 5 10 50 100 1000 10000
A450
0.000 0.500 1.000 1.500 2.000
scFv
60
Fig 28. Antigen (aflatoxin B1) binding activity of codon optimized scFv and MBP fuison protein by indirect ELISA
MBP-scFv op. ELISA
Con. of aflatoxin (ppb)
1 5 10 50 100 1000 10000
A450
0.000 0.500 1.000 1.500 2.000
scFv-op
61
Fig 29. Color reaction of substrate to measure antigen binding activity by indirect ELISA
Aflatoxin B1-BSA concentration 0 ppb ~ 104 ppb
s.s malE Xa scFv H6 0.01 g/L
s.s malE Xa scFv op H6 0.01 g/L
62
Fig 30 Factor Xa protease treatment to take scFv itself
L : Protein Ladder
T : Total (0 hour protease treatment ) T: Total (1 hour protease treatment ) S : Soluble (1 hour protease treatment ) I : Insoluble (1 hour protease treatment )
AFB1 scFv : 26.5 kDa MBP: 42 kDa
scFv-MBP fusion protein: 68.5 kDa Factor Xa protease: 43 kDa
L T L
T SI
30 kDa 40 kDa 50 kDa 60 kDa 70 kDa
25 kDa
63 scFv
Wavelength (nm)
180 200 220 240 260 280
[Q]MRW (deg cm2 dmol-1 )
-4e+6 -3e+6 -2e+6 -1e+6
0 1e+6 2e+6
scFv
Fig 31. Secondary structure analysis of scFv by circular dichroism
64
Fig. 32. Expression of MBP fusion scFv of fumonisin B1 in C41(DE3) at 37°C and 0.2 mM IPTG.
scFv-MBP fusion protein: 69 kDa
L : Protein Ladder
T : Total (Before Induction) T: Total (After Induction) S : Soluble (After Induction) I : Insoluble (After Induction)
65
Fig. 33. Expression of MBP fusion scFv of deoxynivalenol in C41(DE3) at 37°C and 0.2 mM IPTG.
scFv-MBP fusion protein: 69 kDa
L : Protein Ladder
T : Total (Before Induction) T: Total (After Induction) S : Soluble (After Induction) I : Insoluble (After Induction)
66
V. CONCLUSIONS
A robust expression system of E. coli C41(DE3) carrying the scFv-MBP fusion gene were developed to produce soluble and active scFv of aflatoxin B1. The results obtained in this research can be summarized as follows;
1) An expression system for aflatoxin B1 by fusing the scFv with MBP in E. coli C41(DE3) was developed for production of soluble scFv.
2) The expression system can be applied to produce other types of scFv in soluble form such as fumonisin B1 and deoxynivalenol.
3) The E. coli C41(DE3) strain was able to produce the maximum scFv-MBP fusion protein level of 810 mg/L in fed-batch fermentation. Aflatoxin B1 binding activity of scFv and MBP fusion protein was confirmed. The secondary structure of scFv was determined to be the beta sheet by circular dichroism.
67
V. REFERENCES
Alefounder PR, Ferguson SJ (1980) The location of dissimilatory nitrite reductase and the control of dissimilatory nitrate reductase by oxygen in Paracoccus denitrificans. Biochemical Journal 192: 231-240
Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen BNM, Hamid M (2012) scFv antibody: Principles and clinical application. Clinical and
Developmental Immunology 2012: 1-15
Baneyx F, Mujacic M (2004) Recombinant protein folding and misfolding in Escherichia coli. Nature Biotechnology 22: 1399-1408
Bessette PH, Aslund F, Beckwith J, Georgiou G (1999) Efficient folding of proteins with multiple disulfide bonds in the Escherichia coli cytoplasm.
Procedings of the National Academy Sciences 96:13703–13708.
Chen G, Dubrawsky I, Mendez P, Georgiou G, Iverson BL (1999) In vitro scanning saturation mutagenesis of all the specificity determining residues in an antibody binding site. Protein Engineering 12: 349-356
Cho YJ, Lee DH, Kim DO, Min WK, Bong KT, Lee GG, Seo JH (2005) Production of monoclonal antibody against Ochratoxin A and its application to immunochromatographic assay. Journal of Agriculture and Food
Chemistry 53. 8447-8451
68
Choi GH, Lee DH, Min WK, Cho YJ, Kweon DH, Son DH, Park K, Seo JH (2004) Cloning, expression, and characterization of single-chain variable fragment antibody against mycotoxin deoxynivalenol in recombinant Escherichia coli. Protein Expression and Purification 35: 84-92
Choi JH, Lee SY (2004) Secretory and extracellular production of recombinant proteins using Escherichia coli. Applied Microbiology and Biotechnology 64: 625-635
Chowdhury PS, Pastan I (1999) Improving antibody affinity by mimicking somatic hypermutation in vitro. Nature Biotechnology 17: 568-572
de Maagd RA, Lugtenberg B (1986) Fractionation of Rhizobium leguminosarum cells into outer membrane, cytoplasmic membrane, periplasmic, and cytoplasmic components. Journal of Bacteriology 167:
1083-1085
de Marco A (2009) Strategies for successful recombinant expression of disulfide bond-dependent proteins in Escherichia coli. Microbial Cell Factories 8: 26
Dyson MR, Shadbolt SP, Vincent KJ, Perera RL, McCafferty J (2004) Production of soluble mammalian proteins in Escherichia coli: identification of protein features that correlate with successful expression. BMC
Biotechnology 4:32.
69
Gasser B, Saloheimo M, Rinas U, Dragosits M, Rodriguez-Carmona E, Baumann K, Giuliani M, Parrilli E, Branduardi P, Lang C, Porro D, Ferrer P, Tutino M, Mattanovich D, Villaverde A (2008) Protein folding and
conformational stress in microbial cells producing recombinant proteins: a host comparative overview. Microbial Cell Factories 7:11-28
Grisshammer R, Tate CG (1995) Overexpression ofintegral membrane
proteins for structural studies. Quarterly Reviews of Biophysics 28: 315–422.
Hannig G, Makrides SC (1998) Strategies for optimizing heterologous protein expression in Escherichia coli. Trends in Biotechnology 16: 54-60
Jung HJ, Kim SK, Min WK, Lee SS, Park KM, Park YC, Seo JH (2011) Polycationic amino acid tags enhance soluble expression of Candida antarctica lipase B in recombinant Escherichia coli. Bioprocess and Biosystems Engineering 34: 833-839
Makrids SC (1996) Strategies for achieving high-level expression of genes in Escherichia coli. Microbiological Reviews 60: 512–538
Maria DE (2001) Synonymous codon usage in bacteria. Current Issued in Molecular Biology 3(4): 91-97
Kapust RB, Waugh DS (1999) Escherichia coli maltose-binding protein is uncommonly effective at promoting the solubility of polypeptides to which it is fused. Protein Science 8:1668-1674.
70
Kataeva I, Chang J, Xu H, Luan CH, Zhou J, Uversky VN, Lin D,Horanyi P, Liu ZJ, Ljungdahl LG et al (2005) Improving solubility of Shewanella oneidensis MR-1 and Clostridium thermocellum JW-20 proteins expressed into Escherichia coli. Journal of Proteome Research 4:1942-1951.
Kim SG, Shin SY, Park YC, Shin CS, Seo JH (2011) Production and solid-phase refolding of human glucagon-like peptide-1 using recombinant Escherichia coli. Protein Expression and Purificaation 78:197-203
Kolaj O, Spada S, Robin S, Wall JG (2009) Use of folding modulators to improve heterologous protein production in Escherichia coli. Microbial Cell Factories 8:1-17
Kweon DH, Lee DH, Han NS, Rha CS, Seo JH (2002) Characterization of polycationic amino acids fusion systems for ion-exchange purification of cyclodextrin glycosyltransferase from recombinant Escherichia coli.
Biotechnology Progress 18: 303-308
Malamy MH, Horecker BL (1964) Release of alkaline phosphatase from cells of Escherichia coli upon lysozyme spheroplast formation. Biochemistry 3: 1889-1893
Markwell JP, Lascelles J (1978) Membrane-bound, pyridine nucleotide-independent L-lactate dehydrogenase of Rhodopseudomonas sphaeroides.
Journal of Bacteriology 133: 593-600
71
Mergulhão FJM, Summers DK, Monteiro GA (2005) Recombinant protein secretion in Escherichia coli. Biotechnology Advances 23: 177-202
Mergulhao F, Taipa M, Cabral J, Monteiro G (2004) Evaluation of
bottlenecks in proinsulin secretion by Escherichia coli. J Biotechnol 109: 31 – 43
Min WK, Kweon DH, Park KM, Park YC, Seo JH (2011) Characterization of monoclonal antibody against aflatoxin B1 produced in hybridoma 2C12 and its single-chain variable fragment expressed in recombinant Escherichia coli.
Food Chemistry 126 (3):1316 – 1323
Min WK, Cho YJ, Park JB, Bae YH, Kim EJ, Park KM, Park YC, Seo JH (2010) Production and characterization of monoclonal antibody and its recombinant single chain variable fragment specific for a food-born mycotoxin, fumonisin B1. Bioprocess and Biosystems Engineering 33(1):109-115
Miroux B, Walker JE (1996) Over-production of proteins in Eshcerichia coli:
Mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels. Journal of Microbiology and Biotechnology 260, 289-298.
Moghaddam A, Løbersli I, Gebhardt K, Braunagel M, Marvik OJ (2001) Selection and characterisation of recombinant single-chain antibodies to the hapten Aflatoxin-B1 from naive recombinant antibody libraries. Journal of
Moghaddam A, Løbersli I, Gebhardt K, Braunagel M, Marvik OJ (2001) Selection and characterisation of recombinant single-chain antibodies to the hapten Aflatoxin-B1 from naive recombinant antibody libraries. Journal of